220 related articles for article (PubMed ID: 22088674)
1. Development of a live, attenuated, potential vaccine strain of R. equi expressing vapA and the virR operon, and virulence assessment in the mouse.
Whitehead AE; Parreira VR; Hewson J; Watson JL; Prescott JF
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):479-84. PubMed ID: 22088674
[TBL] [Abstract][Full Text] [Related]
2. Foal IgG and opsonizing anti-Rhodococcus equi antibodies after immunization of pregnant mares with a protective VapA candidate vaccine.
Cauchard J; Sevin C; Ballet JJ; Taouji S
Vet Microbiol; 2004 Nov; 104(1-2):73-81. PubMed ID: 15530741
[TBL] [Abstract][Full Text] [Related]
3. Assessment in mice of vapA-DNA vaccination against Rhodococcus equi infection.
Haghighi HR; Prescott JF
Vet Immunol Immunopathol; 2005 Apr; 104(3-4):215-25. PubMed ID: 15734542
[TBL] [Abstract][Full Text] [Related]
4. The effect of mutation on Rhodococcus equi virulence plasmid gene expression and mouse virulence.
Ren J; Prescott JF
Vet Microbiol; 2004 Nov; 103(3-4):219-30. PubMed ID: 15504593
[TBL] [Abstract][Full Text] [Related]
5. Immunization by intrabronchial administration to 1-week-old foals of an unmarked double gene disruption strain of Rhodococcus equi strain 103+.
Pei Y; Nicholson V; Woods K; Prescott JF
Vet Microbiol; 2007 Nov; 125(1-2):100-10. PubMed ID: 17560744
[TBL] [Abstract][Full Text] [Related]
6. Immunogenecity of synthetic peptides representing linear B-cell epitopes of VapA of Rhodococcus equi.
Taouji S; Nomura I; Giguère S; Tomomitsu S; Kakuda T; Ganne V; Takaï S
Vaccine; 2004 Mar; 22(9-10):1114-23. PubMed ID: 15003638
[TBL] [Abstract][Full Text] [Related]
7. Use of Rhodococcus equi virulence-associated protein for immunization of foals against R equi pneumonia.
Prescott JF; Nicholson VM; Patterson MC; Zandona Meleiro MC; Caterino de Araujo A; Yager JA; Holmes MA
Am J Vet Res; 1997 Apr; 58(4):356-9. PubMed ID: 9099378
[TBL] [Abstract][Full Text] [Related]
8. Analysis of anamnestic immune responses in adult horses and priming in neonates induced by a DNA vaccine expressing the vapA gene of Rhodococcus equi.
Lopez AM; Hines MT; Palmer GH; Knowles DP; Alperin DC; Hines SA
Vaccine; 2003 Sep; 21(25-26):3815-25. PubMed ID: 12922115
[TBL] [Abstract][Full Text] [Related]
9. Immune response to vaccines based upon the VapA protein of the horse pathogen, Rhodococcus equi, in a murine model.
Vanniasinkam T; Barton MD; Heuzenroeder MW
Int J Med Microbiol; 2005 Jan; 294(7):437-45. PubMed ID: 15715172
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of a lipid-modified virulence-associated protein of Rhodococcus equi and its potential in protective immunity.
Tan C; Prescott JF; Patterson MC; Nicholson VM
Can J Vet Res; 1995 Jan; 59(1):51-9. PubMed ID: 7704843
[TBL] [Abstract][Full Text] [Related]
11. VapA-specific IgG and IgG subclasses responses after natural infection and experimental challenge of foals with Rhodococcus equi.
Sanz MG; Villarino N; Ferreira-Oliveira A; Horohov DW
Vet Immunol Immunopathol; 2015 Mar; 164(1-2):10-5. PubMed ID: 25681111
[TBL] [Abstract][Full Text] [Related]
12. Nasal vaccination with attenuated Salmonella expressing VapA: TLR2 activation is not essential for protection against R. equi infection.
Cardoso SA; Oliveira AF; Ruas LP; Trevisani MM; De Oliveira LL; Hanna ES; Roque-Barreira MC; Soares SG
Vaccine; 2013 Sep; 31(41):4528-35. PubMed ID: 23933366
[TBL] [Abstract][Full Text] [Related]
13. The LysR-type transcriptional regulator VirR is required for expression of the virulence gene vapA of Rhodococcus equi ATCC 33701.
Russell DA; Byrne GA; O'Connell EP; Boland CA; Meijer WG
J Bacteriol; 2004 Sep; 186(17):5576-84. PubMed ID: 15317761
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a live-attenuated auxotrophic candidate vaccine against the intracellular pathogen Rhodococcus equi.
Lopez AM; Townsend HG; Allen AL; Hondalus MK
Vaccine; 2008 Feb; 26(7):998-1009. PubMed ID: 18055071
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of a live attenuated Salmonella vaccine strain expressing the VapA protein induces protection against infection by Rhodococcus equi.
Oliveira AF; Ferraz LC; Brocchi M; Roque-Barreira MC
Microbes Infect; 2007 Mar; 9(3):382-90. PubMed ID: 17307012
[TBL] [Abstract][Full Text] [Related]
16. Chimeric vapA/groEL2 DNA vaccines enhance clearance of Rhodococcus equi in aerosol challenged C3H/He mice.
Phumoonna T; Barton MD; Vanniasinkam T; Heuzenroeder MW
Vaccine; 2008 May; 26(20):2457-65. PubMed ID: 18423949
[TBL] [Abstract][Full Text] [Related]
17. The steroid catabolic pathway of the intracellular pathogen Rhodococcus equi is important for pathogenesis and a target for vaccine development.
van der Geize R; Grommen AW; Hessels GI; Jacobs AA; Dijkhuizen L
PLoS Pathog; 2011 Aug; 7(8):e1002181. PubMed ID: 21901092
[TBL] [Abstract][Full Text] [Related]
18. Failure of a VapA/CpG oligodeoxynucleotide vaccine to protect foals against experimental Rhocococcus equi pneumonia despite induction of VapA-specific antibody and interferon-γ response.
Lohmann KL; Lopez AM; Manning ST; Marques FJ; Brownlie R; Allen AL; Sangster AE; Mutwiri G; Gerdts V; Potter A; Townsend HG
Can J Vet Res; 2013 Jul; 77(3):161-9. PubMed ID: 24101791
[TBL] [Abstract][Full Text] [Related]
19. Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against Rhodococcus equi infection.
Cauchard S; Bermúdez-Humarán LG; Blugeon S; Laugier C; Langella P; Cauchard J
Vaccine; 2011 Dec; 30(1):95-102. PubMed ID: 22019740
[TBL] [Abstract][Full Text] [Related]
20. Mouse lung infection model to assess Rhodococcus equi virulence and vaccine protection.
González-Iglesias P; Scortti M; MacArthur I; Hapeshi A; Rodriguez H; Prescott JF; Vazquez-Boland JA
Vet Microbiol; 2014 Aug; 172(1-2):256-64. PubMed ID: 24852140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
